

# Alfonso Vignoli

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10742806/publications.pdf>

Version: 2024-02-01

20  
papers

1,228  
citations

623734

14  
h-index

752698

20  
g-index

20  
all docs

20  
docs citations

20  
times ranked

1390  
citing authors

#	ARTICLE	IF	CITATIONS
1	Increased platelet thrombus formation under flow conditions in whole blood from polycythaemia vera patients. <i>Blood Transfusion</i> , 2021, , .	0.4	1
2	Thrombin generation predicts early recurrence in breast cancer patients. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 2220-2231.	3.8	17
3	Thrombotic biomarkers for risk prediction of malignant disease recurrence in patients with early stage breast cancer. <i>Haematologica</i> , 2020, 105, 1704-1711.	3.5	21
4	Acute promyelocytic leukemia cell adhesion to vascular endothelium is reduced by heparins. <i>Annals of Hematology</i> , 2018, 97, 1555-1562.	1.8	13
5	Mechanisms and risk factors of thrombosis in cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2017, 118, 79-83.	4.4	183
6	Heparins inhibit the endothelial pro-thrombotic features induced by tumor cells. <i>Thrombosis Research</i> , 2017, 157, 55-57.	1.7	4
7	Hypercoagulation screening as an innovative tool for risk assessment, early diagnosis and prognosis in cancer: the HYPERCAN study. <i>Thrombosis Research</i> , 2016, 140, S55-S59.	1.7	29
8	Tissue Factor Expression on Platelet Surface during Preparation and Storage of Platelet Concentrates. <i>Transfusion Medicine and Hemotherapy</i> , 2013, 40, 126-132.	1.6	11
9	LMWH Bemiparin and ULMWH RO-14 Reduce the Endothelial Angiogenic Features Elicited by Leukemia, Lung Cancer, or Breast Cancer Cells. <i>Cancer Investigation</i> , 2011, 29, 153-161.	1.3	24
10	Comparative assessment of low-molecular-weight heparins in cancer from the perspective of patient outcomes and survival. <i>Patient Related Outcome Measures</i> , 2011, 2, 175.	1.2	15
11	Nitric oxide derivatives and soluble plasma selectins in patients with myeloproliferative neoplasms. <i>Thrombosis and Haemostasis</i> , 2010, 104, 151-156.	3.4	51
12	Bemiparin in Oncology. <i>Drugs</i> , 2010, 70, 35-42.	10.9	8
13	Coagulation in Hematological Malignancies. <i>Cancer Investigation</i> , 2009, 27, 7-16.	1.3	1
14	Endothelial capillary tube formation and cell proliferation induced by tumor cells are affected by low molecular weight heparins and unfractionated heparin. <i>Thrombosis Research</i> , 2008, 121, 637-645.	1.7	80
15	V617F JAK-2 mutation in patients with essential thrombocythemia: relation to platelet, granulocyte, and plasma hemostatic and inflammatory molecules. <i>Experimental Hematology</i> , 2007, 35, 702-711.	0.4	169
16	Differential effect of the low-molecular-weight heparin, dalteparin, and unfractionated heparin on microvascular endothelial cell hemostatic properties. <i>Haematologica</i> , 2006, 91, 207-14.	3.5	31
17	Leukocyte-platelet interaction in patients with essential thrombocythemia and polycythemia vera. <i>Experimental Hematology</i> , 2005, 33, 523-530.	0.4	212
18	All-trans retinoic acid modulates microvascular endothelial cell hemostatic properties. <i>Haematologica</i> , 2003, 88, 895-905.	3.5	24

#	ARTICLE	IF	CITATIONS
19	Clotting mechanisms and cancer: implications in thrombus formation and tumor progression. <i>Clinical Advances in Hematology and Oncology</i> , 2003, 1, 673-8.	0.3	75
20	Polymorphonuclear leukocyte activation and hemostasis in patients with essential thrombocythemia and polycythemia vera. <i>Blood</i> , 2000, 96, 4261-4266.	1.4	259